Ftse Mib
33.986,90
1,06%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.276,12
-1,13%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Anixa Biosciences Inc (ANIX) Anixa Biosciences Inc (ANIX) Notizie

Anixa Biosciences Inc

ANIX
3,02
0,08 (2,72%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:59:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/5/202414:05PRNUSAnixa Biosciences CEO Featured on "Target: Cancer Podcast"..
30/4/202413:45PRNUSAnixa Biosciences to Participate in the Sidoti Micro-Cap..
18/4/202414:20PRNUSAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay..
14/3/202413:45PRNUSAnixa Biosciences 2024 Annual Meeting of Stockholders to..
11/3/202413:00PRNUSAnixa Biosciences Announces Presentation at 24th Annual..
12/2/202413:30PRNUSAnixa Biosciences Initiates Dosing in Second Cohort of..
08/2/202422:15EDGAR2Form DEF 14A - Other definitive proxy statements
29/1/202414:50PRNUSAnixa Biosciences Announces Participation in 2024..
23/1/202413:55PRNUSAnixa Biosciences Announces Japanese Patent on Ovarian..
17/1/202401:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202423:29EDGAR2Form SC 13D/A - General statement of acquisition of..
16/1/202422:43EDGAR2Form S-8 - Securities to be offered to employees in employee..
16/1/202422:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
10/1/202415:00PRNUSAnixa Biosciences to Present at Sidoti Micro-Cap Virtual..
14/12/202313:15PRNUSAnixa Biosciences to Present at Biotech Showcase 2024
07/12/202312:01EDGAR2Form 8-K - Current report
07/12/202300:00PRNUSAnixa Biosciences and Cleveland Clinic Present Positive New..
06/12/202322:05PRNUSAnixa Biosciences to Host Conference Call This Evening to..
27/11/202314:30PRNUSAnixa Biosciences Announces European Patent on Ovarian..
02/11/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202313:30PRNUSAnixa Biosciences to Present at the Ovarian Cancer Research..
23/10/202314:30PRNUSAnixa Biosciences Appoints Accomplished Medical Oncologist..
13/10/202314:30PRNUSAnixa Biosciences Completes Treatment of First Patient..
11/10/202316:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202314:30PRNUSAnixa Biosciences Announces Issuance of Additional U.S...
19/9/202314:30PRNUSAnixa Biosciences Establishes Cancer Business Advisory Board
06/9/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/8/202314:30PRNUSAnixa Biosciences to Participate in September Investor..
28/8/202314:30PRNUSAnixa Biosciences Announces Treatment of Third Patient in..
14/8/202314:30PRNUSAnixa Biosciences Announces Invited Presentation on Ovarian..
07/8/202314:30PRNUSAnixa Biosciences Announces Opening of Enrollment for..
01/8/202300:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202300:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202314:30PRNUSAnixa Biosciences Announces Notice of Allowance of..
21/7/202316:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202314:30PRNUSAnixa Biosciences Announces Issuance of Canadian Patent for..
22/5/202314:30PRNUSAnixa Biosciences Announces Treatment of Second Patient in..
Apertura: 2,97 Min: 2,96 Max: 3,05
Chiusura: 2,94

La tua Cronologia

NASDAQ
ANIX
Anixa Biosciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network